Coala Life: Refilled growth capital - Redeye
Redeye updates its estimates and valuation following Coala Life’s recent rights issue, securing cSEK55m in growth capital and resulting in a 75% dilution for non-participating shareholders. CEO Dan Pitulia continues to demonstrate his commitment by investing SEK7m in the rights issue. Our revised estimates reflect the recent development in patient ramp-up for remote monitoring (PRM) and the announced cost-saving program. In our updated valuation, we also factor in an anticipated cash injection of SEK12m from the warrants due in Q2 2024 -our new Base case is SEK0.12 (SEK1.3) per share.
Länk till analysen i sin helhet: https://www.redeye.se/research/971696/coala-life-refilled-growth-capital?utm_source=finwire&utm_medium=RSS